Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903083 · ClinicalTrials.gov registry record · Phase 1
Chemoimmunotherapy and Radiation in Pancreatic Cancer
A Phase 1 study of Locally Advanced Malignant Neoplasm, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01903083 is a Phase 1 study of Locally Advanced Malignant Neoplasm that has completed, run by Providence Health & Services. The registered enrollment target is 10 participants, below the 123-participant average among 11 other Locally Advanced Malignant Neoplasm trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01903083, a Phase 1 study of Locally Advanced Malignant Neoplasm, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.
Conditions Studied
Interventions
- DRUG Gemcitabine
- RADIATION Radiation
- DRUG Tadalafil
- PROCEDURE Pancreaticoduodenectomy
Study Locations (1)
Oregon
- Portland Providence Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01903083
The ClinicalTrials.gov registry entry for NCT01903083 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 11 other Locally Advanced Malignant Neoplasm trials with a reported enrollment target (92% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Malignant Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Gemcitabine is the first listed.
NCT01903083 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT01903083 about?
NCT01903083 is a clinical study titled "Chemoimmunotherapy and Radiation in Pancreatic Cancer". The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.
What is the current status of trial NCT01903083?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-07. Estimated completion is 2017-12.
What conditions does trial NCT01903083 study?
This clinical trial studies the following conditions: Locally Advanced Malignant Neoplasm.
What interventions are being tested in trial NCT01903083?
The interventions under investigation include: Gemcitabine (DRUG), Radiation (RADIATION), Tadalafil (DRUG), Pancreaticoduodenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT01903083?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01903083 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
COMPLETED · Phase 1
-
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
COMPLETED · Phase 1
-
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
ACTIVE NOT RECRUITING · NA
-
Financial Distress in Advanced Cancer Patients
ACTIVE NOT RECRUITING
-
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.